DNL-151 | Interleukin Related interleukin-related.com

Product Name :
DNL-151

Search keywords :
LRRK2

drugId :
null

Target Vo:
Leucine-rich repeat serine/threonine-protein kinase 2

Target Vo Short Name :
LRRK2

Moa_Name:
Leucine-rich repeat serine/threonine-protein kinase 2 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Genentech Inc

Active Company_Name :
Biogen Idec Research Ltd

Active Indication_Name:
Parkinson Disease

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 2 Clinical

China Highest Status:
Phase 2 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
CD40L Antibody
MMP1 Antibody
FGF2 Antibody: FGF2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 31 kDa, targeting to FGF2. It can be used for WB assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts